In breast cancer, Nrf2 activation leads to the overexpression of Rho and the downstream proteins FAK (focal adhesion kinase 1), MLC (modulator of volume-regulated anion channel current 1), and ROCK (Rho-associated coiled-coil-containing protein kinase 1), while inhibiting the expression of estrogen-related receptor α (ERR1). This evidence concerns the gene NFE2L2 and breast cancer.